SÍNDROME DE STEVENS-JOHNSON: REPORTE DE UN CASO
El síndrome de Stevens-Johnson es una entidad de baja prevalencia que muchas veces requiere internación en unidades de cuidados críticos, siendo necesario un diagnóstico precoz y un tratamiento oportuno de urgencia en el que se incluyan las medidas de sostén y el tratamiento farmacológico, solo así será posible disminuir la morbimortalidad y las potenciales secuelas que puede causar esta enfermedad.
Institución del autor
Clínica Privada Independencia, Munro, Argentina
Coautores
Zaith de Jesús Saurith Daza* Sandra Carolina Benítez Arce**
Médico, Clínica Privada Independencia, Munro, Argentina*
Médica, Clínica Privada Independencia, Munro, Argentina**
Palabras clave
síndrome de Stevens-Johnson, signo de Nikolsky, necrólisis epidérmica tóxica, factor de necrosis tumoral, escala de scorten, corticosteroides
Clasificación en siicsalud
Artículos originales >
Expertos de iberoamérica
>
página
http://siicsa.ddns.net/dato/casiic.php/174906
Especialidades
Primera edición en siicsalud
25 de octubre, 2024
Bibliografía del caso clínico
1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophtalmia: report of two cases in children. Am J Dis Child 526-533; 1992.
2. Miliszewski MA, Kirchhof MG, Sikora S, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: an analysis of triggers and implications for improving prevention. Am J Med 129: 1221-5; 2016.
3. Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. Joyrnal os Investigative Dermatology 137(6):1240-1247; 2017.
4. Ferrándiz-Pulido C, García-Fernández D, Gómez-Morell P, Palao R, García-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the clinical experience of a University Hospital (1989-2008).Med Clin (Barc) 583-587; 2011.
5. Martinez S, Gómez M, Ocampo J. Actualidades en farmacodermias severas:síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica. Gac Med Mex 151:777-87; 2015.
6. Bastuji-Garin S, Bertocchi M, Roujeau JC, et al: SCORTEN: A severety of illness Score for Toxic Ephdermal Necrolysis. J Invest Dermatol 115:149-153; 2000.
7. Grünwald P, Mockenhaupt M, Panzer R, Emmert S: Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. JDtsch Dermatol Ges 18(6):547-53; Jun 2020.
8. Kohanim S, Palioura S, Saeed HN, et al. Stevens-Johnson/Toxic Epidermal necrolysis: A Comprehensive Review and Guide to therapy. I. Systemic Disease. Ocul Surf 14(1):2-19; 2016.
9. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60-8; 2010.
10. Revuz J, Penso D, Roujeau JC. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 123:1160-1165; 1987.
11. Roujeau JC, Kelly JP, Naldi L, Stern RS, Anderson T et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600-1607; 1995
12. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxicepidermal necrolysis (liell syndrome). J Am Acad Dermatol 23:1039-1058; 1990.
13. Chan H. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 10:973-978; 1984.
14. Zweibaum B, Cohen H, Chandrasoma P. Gastrointestinal involvement complicating drug-induced toxic epidermal necrolysis. Gastroenterolgy 91:469-474; 1986.
15. Tatnall FM, Dodd HJ, Sarkany I. Elevation serum amylase in a case of toxic epidermal necrolysis. Br J Dermatol 113:629-30; 1985.
16. Goens J, Song M, Fondu P, Blum D, Achten G. Haematological disturbances and immune mechanisms in toxic epidermal necrolysis. Vr J Dermatol 115:255-259; 1985.
17. Westly ED, Weschler HL, Toxic epidermal necrlolysis:granulocytic leukopenia as a prognostic indicator. Arch Dermatol 120:721-726; 1984.
18. Kvasnicka J, Rezac J, Svejda J, et al. Disseminated intravascular coagulation associated with toxic epidermal necrolysis (Lyell's disease). Br J Dermatol 100:551-558; 1979.
19. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson síndrome and toxic epidermal necrolysis. Review F1000Res. 2020. 9(F1000 Faculty Rev):612, Jun 2020.
20. Harris V, Jackson C, Cooper A. Review of toxic epidermal necrolysis. Int J Mol Sci. 17:1-11; 2016.
21. Brickel N, Shaikh H, Kirkham A, Davies G, Chalker M, Yoshida P. Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions-are view of spontaneous reports.Ther Clin Risk Manag 13:897-903; 2017.
22. Valeyrie Allanore L, Bastuji-Garin S, Guégan S, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol (68):29-35; 2013.
23. Su SC, Mockenhaupt M, Wolkenstein P. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol 137(5):1065-1073; 2017.
24. Posadas S, Padial A, Torres M, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Inmunol. 109(1):155-161; 2002.
25. Chung WH, Hung SI, Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergology International 59(4): 325-32; 2010.
26. Chun WH, Hung SI, Yang YJ, et al. Granulysin is a key mediator for disseminated keratinocyteb death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343-1350; 2008.
27. Hasegawa A, Shinkuma S, Hayashi R. RIP3 as a diagnosis and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Inmunol Pract 8(5):1768-1771; 2020.
28. Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina 57(9),895; 2021.
29. Harris V, Jackson C, Cooper A. Review of toxic epidermal necrolysis. Int J Mol Sci. 17:1-11; 2016.
30. Dodiuk-Gad RP, Valeyrie-Allanore L, Shear NH. Steven-Johnson syndrome and toxic epidermal necrolysis: An update. Am J Clin Dermatol 16:475-493; 2015.
31. Pacheco L, Sanchez MA, Sanchez DL. Síndrome de Stevens Johnson. Presentación de un caso. Rev Cubana Pediatr 73(4):240-245; 2001.
32. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infects Dis J 1:155-158; 1982.
33. Kelemen JJ 3rd, Cioffi WG, McManus WF, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 180(3):273-278; 1995.
34. Shiga S, Cartotto R. What Are the Fluid Requirements in Toxic Epidermal Necrolysis? J Burn Care Res 31(1):100-4; 2010.
35. Coss-Bu JA, Jefferson LS, Levy ML, et al. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 12(2):81-84; 1997.
36. Valeyrie-Allanore L, Ingen-Housz-Oro S, Chosidow O, et al. French referral center management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Dermatologica Sinica 31(4):191-5; 2013.
37. De Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteriemia in Stevens-Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 89(1):28-36; 2010.
38. Zimmerman S, Sekula P, Venhoff M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol 153(6):514-522; 2017.
39. Roujeau JC, Bastuji-Garin S: Systematic review of treatments for Steven-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf 2(3):87-94; 2011.
40. Kardaun SH, Jonkman MF. Dexamethasone Pulse Therapy for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Acta Derm Venereol 87(2):144-8; 2007.
41. Lee HY, Lim YL, Thirumoorthy T, et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: A retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 169(6):1304-1309; 2013.
42. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous inmunoglobulins (IV Ig): Clinical experience to date. Drugs 65(15):2085-90; 2005.
43. Huang YC, Li YC, Chen TJ: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systemic review and meta-analysis. Br J Dermatol 167(2):424-432; 2012.
44. Barron SJ, Del Vecchio MT, Aronoff SC: Intravenous immunoglobulin in the treatment of Steven-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies. Int J Dermatol 54(1):108-115; 2015.
45. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163(4):847-853; 2010.
46. Kirchhof MG, Miliszewski MA, Sikora S, et al.: Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71(5):941-947; 2014.
47. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al.: Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol 137(10):2092-2100; 2017.
48. Shah R, Chen ST, Kroshinsky D. Use of Cyclosporine for the treatment of Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis. J Am Acad Dermatol 85(2):512-513; 2019.
49. Gilbert M, Scherrer LA: Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Ther. 32(1): e12758, 2019.
50. Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 6(3):225-228; 2002.
51. Yamada H, Takamori K, Yaguchi H, et al. A Study of the Efficacy of Plasmapheresis for the Treatment of Drug Induced Toxic Epidermal Necrolysis. Ther Apher 2(2):153-156; 1998.
52. Narita YM, Hirahara K, Mizukawa Y, et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 38(3): 236-345; 2011.
53. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: Preliminary report. Br J Plast Surg 58(4): 504-510; 2005.
54. Han F, Zhang J, Guo Q, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. J Crit Care 42: 65-68; 2017.
55. Wojtkiewicz A, Wysocki M, Fortuna J, et al.: Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 88(4): 420-431; 2008.
56. Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 23(1): 61-63; 2013.
57. Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 71(2): 278-283; 2014.
58. Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116(4): 923-934; 2005.
59. Gubinelli E, Canzona F, Tonanzi T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 36(3): 150-153; 2009.
60. Patmanidis K, Sidiras A, Dolianitis K, et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: Successful treatment of an elderly patient. Case Rep Dermatol Med 2012: 915314; 2012.
61. Pham CH, Gillenwater TJ, Nagengast E, et al. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Burns 45(7): 1634-1638; 2019.
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los
contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin
previo y expreso consentimiento de SIIC.
